Genmab AS GMAB

Morningstar Rating
DKK 3,469.00 −28.00 (0.80%)
View Full Chart

Company Report

Price vs Fair Value

GMAB is trading at a LOCK|?JKbmr premium.
Price
DKK 3,469.00
Fair Value
LOCK|<$
Uncertainty
LOCK|xk?w
1-Star Price
LOCK|bL
5-Star Price
LOCK|%#
Economic Moat
LOCK|WbpNs
Capital Allocation
LOCK|H>qy&Z

Bulls Say, Bears Say

Bulls

Darzalex is entrenched in the standard of care for multiple myeloma, and it is unlikely any competitors will completely displace it due to its robust efficacy and well-tolerated safety profile.

Bears

Large acquisitions and heavy R&D spending increase financial risk if new drugs fail to meet expectations or achieve meaningful commercial uptake.

News

Trading Information

Previous Close Price
DKK 3,497.00
Day Range
DKK 3,465.00–3,515.00
52-Week Range
DKK 1,512.00–3,947.00
Bid/Ask
DKK 3,474.00 / DKK 3,477.00
Shares Outstanding
61.66M
Market Cap
DKK 213.90B
Volume/Avg
123,604 / 152,305

Key Statistics

Price/Earnings (Normalized)
34.12
Price/Sales
7.83
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
3,244

Competitors

Valuation

Metric
GMAB
INCY
4502
Price/Earnings (Normalized)
34.1246.1145.00
Price/Book Value
5.114.141.50
Price/Sales
7.833.962.35
Price/Cash Flow
34.4821.3615.72
Price/Earnings
GMAB
INCY
4502

Financial Strength

Metric
GMAB
INCY
4502
Quick Ratio
2.433.540.52
Current Ratio
2.453.841.15
Interest Coverage
2.74283.921.70
Quick Ratio
GMAB
INCY
4502

Profitability

Metric
GMAB
INCY
4502
Return on Assets (Normalized)
10.39%9.15%5.67%
Return on Equity (Normalized)
20.28%11.94%11.63%
Return on Invested Capital (Normalized)
14.10%10.07%7.93%
Return on Assets
GMAB
INCY
4502

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|VVJ%?@RLOCK|?#>$$131B
Regeneron Pharmaceuticals Inc
REGN
LOCK|!#WCj%@LOCK|qg>l$95B
Moderna Inc
MRNA
LOCK|MLQ%^vLOCK|$#$79B
argenx SE ADR
ARGX
LOCK|!@L?!?LOCK|bz>$59B
BeOne Medicines Ltd ADR
ONC
LOCK|@@?@z@?LOCK|r&b$45B
Royalty Pharma PLC Class A
RPRX
LOCK|!yRlxM#vLOCK|y$?P$30B
Incyte Corp
INCY
LOCK|^JLb@<HLOCK|d%%$23B
BioNTech SE ADR
BNTX
LOCK|t$BvXnrLOCK|?Q$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|%%J>dZQLOCK|kvP@D$19B
BridgeBio Pharma Inc
BBIO
LOCK|>$FBW!<LOCK|rM$15B

Sponsor Center